| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $5,906,060 | 49 | 100 |
| Eisele Jeffrey | Chief Development Officer | 0 | $0 | 4 | $57,149 | $-57,149 |
| Chopas James George | VP/Chief Accounting Officer | 0 | $0 | 6 | $110,455 | $-110,455 |
| DeLong Mark Jeffrey | Chief Business & Strat Officer | 0 | $0 | 5 | $146,503 | $-146,503 |
| Lewis Karen | Chief People Officer | 0 | $0 | 4 | $147,094 | $-147,094 |
| Baumal Caroline | Chief Medical Officer | 0 | $0 | 2 | $150,727 | $-150,727 |
| Sullivan Timothy Eugene | Chief Financial Officer | 0 | $0 | 4 | $224,185 | $-224,185 |
| Deschatelets Pascal | Chief Scientific Officer | 0 | $0 | 4 | $232,645 | $-232,645 |
| Townsend Adam J. | Chief Commercial Officer | 0 | $0 | 4 | $264,626 | $-264,626 |
| Nicholson Nur | Chief Technical Officer | 0 | $0 | 4 | $284,281 | $-284,281 |
| Watson David O. | General Counsel | 0 | $0 | 6 | $641,031 | $-641,031 |
| Francois Cedric | Chief Executive Officer | 0 | $0 | 4 | $854,932 | $-854,932 |
| Dunlop A. Sinclair | director | 0 | $0 | 2 | $2.79M | $-2.79M |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Over the last 12 months, insiders at Apellis Pharmaceuticals, Inc. have bought $0 and sold $5.91M worth of Apellis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Apellis Pharmaceuticals, Inc. have bought $20M and sold $32.79M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500,000 shares for transaction amount of $20M was made by Morningside Venture Investments Ltd (10 percent owner) on 2021‑11‑18.
| 2025-03-17 | Sale | Chopas James George | VP/Chief Accounting Officer | 183 0.0001% | $24.82 | $4,543 | -24.45% | |
| 2025-03-05 | Sale | Watson David O. | General Counsel | 5,569 0.0043% | $25.10 | $139,789 | -24.38% | |
| 2025-02-11 | Sale | DeLong Mark Jeffrey | Chief Business & Strat Officer | 363 0.0003% | $28.54 | $10,360 | -20.79% | |
| 2025-01-29 | Sale | Deschatelets Pascal | Chief Scientific Officer | 826 0.0007% | $29.52 | $24,386 | -18.36% | |
| 2025-01-29 | Sale | Francois Cedric | Chief Executive Officer | 2,824 0.0023% | $29.52 | $83,375 | -18.36% | |
| 2025-01-29 | Sale | Watson David O. | General Counsel | 695 0.0006% | $29.52 | $20,519 | -18.36% | |
| 2025-01-29 | Sale | Sullivan Timothy Eugene | Chief Financial Officer | 546 0.0004% | $29.52 | $16,120 | -18.36% | |
| 2025-01-29 | Sale | DeLong Mark Jeffrey | Chief Business & Strat Officer | 365 0.0003% | $29.52 | $10,776 | -18.36% | |
| 2025-01-29 | Sale | Townsend Adam J. | Chief Commercial Officer | 695 0.0006% | $29.52 | $20,519 | -18.36% | |
| 2025-01-29 | Sale | Nicholson Nur | Chief Technical Officer | 825 0.0007% | $29.52 | $24,357 | -18.36% | |
| 2025-01-29 | Sale | Lewis Karen | Chief People Officer | 364 0.0003% | $29.52 | $10,747 | -18.36% | |
| 2025-01-29 | Sale | Eisele Jeffrey | Chief Development Officer | 278 0.0002% | $29.52 | $8,208 | -18.36% | |
| 2025-01-22 | Sale | Deschatelets Pascal | Chief Scientific Officer | 3,948 0.0032% | $30.43 | $120,120 | -20.35% | |
| 2025-01-22 | Sale | Francois Cedric | Chief Executive Officer | 13,551 0.0109% | $30.43 | $412,296 | -20.35% | |
| 2025-01-22 | Sale | Watson David O. | General Counsel | 3,323 0.0027% | $30.43 | $101,104 | -20.35% | |
| 2025-01-22 | Sale | Sullivan Timothy Eugene | Chief Financial Officer | 3,088 0.0025% | $30.43 | $93,954 | -20.35% | |
| 2025-01-22 | Sale | Townsend Adam J. | Chief Commercial Officer | 3,323 0.0027% | $30.43 | $101,104 | -20.35% | |
| 2025-01-22 | Sale | DeLong Mark Jeffrey | Chief Business & Strat Officer | 1,396 0.0011% | $30.43 | $42,474 | -20.35% | |
| 2025-01-22 | Sale | Nicholson Nur | Chief Technical Officer | 3,948 0.0032% | $30.43 | $120,120 | -20.35% | |
| 2025-01-22 | Sale | Lewis Karen | Chief People Officer | 1,751 0.0014% | $30.43 | $53,275 | -20.35% |
| Deschatelets Pascal | Chief Scientific Officer | 1147716 0.9132% | $21.24M | 0 | 40 | |
| Francois Cedric | Chief Executive Officer | 415695 0.3308% | $7.69M | 0 | 33 | |
| Watson David O. | General Counsel | 138730 0.1104% | $2.57M | 0 | 22 | |
| Sullivan Timothy Eugene | Chief Financial Officer | 128665 0.1024% | $2.38M | 1 | 14 | +1.94% |
| Dunlop A. Sinclair | director | 100000 0.0796% | $1.85M | 0 | 25 | |
| Townsend Adam J. | Chief Commercial Officer | 84050 0.0669% | $1.56M | 0 | 24 | |
| DeLong Mark Jeffrey | Chief Business & Strat Officer | 83945 0.0668% | $1.55M | 0 | 23 | |
| Nicholson Nur | Chief Technical Officer | 83664 0.0666% | $1.55M | 0 | 9 | |
| Lewis Karen | Chief People Officer | 70251 0.0559% | $1.3M | 0 | 15 | |
| Eisele Jeffrey | Chief Development Officer | 55312 0.044% | $1.02M | 0 | 15 | |
| Baumal Caroline | Chief Medical Officer | 53707 0.0427% | $994,123.42 | 0 | 3 | |
| Chopas James George | VP/Chief Accounting Officer | 47955 0.0382% | $887,647.05 | 0 | 11 | |
| Morningside Venture Investments Ltd | 10 percent owner | 12806342 10.1895% | $237.05M | 9 | 0 | +6.91% |
| venBio Global Strategic Fund II L.P. | 10 percent owner | 3579305 2.8479% | $66.25M | 1 | 0 | +31.35% |
| Hillhouse Capital Management, Ltd. | 10 percent owner | 3527152 2.8064% | $65.29M | 1 | 0 | +31.35% |
| Cormorant Asset Management, LLC | 10 percent owner | 3473925 2.7641% | $64.3M | 1 | 0 | +31.35% |
| Machiels Alec | director | 367420 0.2923% | $6.8M | 0 | 44 | |
| Grossi Federico | Chief Medical Officer | 94884 0.0755% | $1.76M | 0 | 43 | |
| SCHEIBLER LUKAS | Chief Research Officer | 68299 0.0543% | $1.26M | 1 | 12 | <0.0001% |
| Brown Victoria L. | Program Team Lead | 24974 0.0199% | $462,268.74 | 0 | 2 | |
| FONTEYNE PAUL R. | director | 5000 0.004% | $92,550.00 | 1 | 0 | +15.13% |
| Perry Nicole D | Vice President - Accounting | 4847 0.0039% | $89,717.97 | 0 | 10 |
$20,297,544 | 73 | 103.06% | $2.16B | |
$11,588,217 | 69 | 42.07% | $3.01B | |
$1,376,668 | 53 | 18.46% | $2.19B | |
$224,368,761 | 42 | 28.26% | $2.25B | |
$140,165,669 | 33 | 85.24% | $2.55B | |
$5,066,938 | 27 | 26.38% | $2.41B | |
$1,801,511 | 23 | 18.58% | $2.25B | |
Apellis Pharmaceuticals, Inc. (APLS) | $174,105,409 | 15 | 10.88% | $2.33B |
$91,269,919 | 12 | 12.86% | $2.94B | |
$75,296,816 | 12 | 37.23% | $2.05B | |
$70,151,579 | 12 | 22.57% | $2.99B | |
$35,908,794 | 10 | 126.31% | $2.89B | |
$1,248,715 | 10 | 5.66% | $2.26B | |
$117,959,652 | 9 | -12.47% | $2.56B | |
$55,713,031 | 8 | -0.36% | $2.56B | |
$25,073,947 | 7 | -5.99% | $2.05B | |
$276,224 | 2 | -7.04% | $2.17B | |
$49,999,992 | 1 | 50.02% | $2.4B | |
$9,900,000 | 1 | -7.19% | $2.08B |
| Increased Positions | 139 | +44.55% | 16M | +12.62% |
| Decreased Positions | 135 | -43.27% | 16M | -12.25% |
| New Positions | 48 | New | 4M | New |
| Sold Out Positions | 58 | Sold Out | 6M | Sold Out |
| Total Postitions | 316 | +1.28% | 130M | +0.37% |
| Avoro Capital Advisors Llc | $248,600.00 | 9.7% | 12.22M | +1M | +10% | 2024-12-31 |
| Ecor1 Capital, Llc | $241,860.00 | 9.44% | 11.89M | 0 | 0% | 2024-12-31 |
| Wellington Management Group Llp | $240,029.00 | 9.37% | 11.8M | -4M | -24.19% | 2024-12-31 |
| Vanguard Group Inc | $204,336.00 | 7.97% | 10.05M | +230,450 | +2.35% | 2024-12-31 |
| Morgan Stanley | $195,818.00 | 7.64% | 9.63M | +6M | +184.01% | 2024-12-31 |
| Blackrock, Inc. | $128,744.00 | 5.02% | 6.33M | -148,391 | -2.29% | 2025-03-31 |
| State Street Corp | $92,042.00 | 3.59% | 4.53M | +484,294 | +11.98% | 2024-12-31 |
| Deep Track Capital, Lp | $86,952.00 | 3.39% | 4.27M | -125,733 | -2.86% | 2024-12-31 |
| Octagon Capital Advisors Lp | $61,162.00 | 2.39% | 3.01M | 0 | 0% | 2024-12-31 |
| Siren, L.L.C. | $57,283.00 | 2.24% | 2.82M | +649,034 | +29.95% | 2024-12-31 |